Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsParkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stabilityPINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's diseaseGenetics of Parkinson's disease - a clinical perspectiveGene-environment interactions: key to unraveling the mystery of Parkinson's diseaseImpaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient micePathway-specific dopaminergic deficits in a mouse model of Angelman syndromeFunctional dynamics of primate cortico-striatal networks during volitional movementsThe role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.The role of biomarkers and imaging in Parkinson's disease.Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype.DJ-1, PINK1, and their effects on mitochondrial pathwaysFamilial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutationsImaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.The genetics of Parkinson disease.Looking backward to move forward: early detection of neurodegenerative disorders.Genetic testing in Parkinson's disease.Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic FormPINK1 mutation heterozygosity and the risk of Parkinson's disease.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Parkinson's disease: the genetics of a heterogeneous disorder.Cell therapy for Parkinson's disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease.Molecular imaging in hereditary forms of parkinsonism.Abnormal Development of Glutamatergic Synapses Afferent to Dopaminergic Neurons of the Pink1(-/-) Mouse Model of Parkinson's Disease.Susceptibility genes in movement disorders.Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease.PINK1 mutations and parkinsonism.Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.Rab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease.Milestones in neuroimaging.The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.The neuropathology of genetic Parkinson's disease.Biomarkers for trials of neuroprotection in Parkinson's disease.Parkinson's disease: from genetics to clinical practice.Biomarkers in Prodromal Parkinson Disease: a Qualitative Review.Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers.PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.Genetics of Parkinson's disease and parkinsonism.Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1.
P2860
Q21129423-B14486EC-F25F-4EF3-8E80-7991BC1C5D35Q24292901-AB0B3C2E-7C4B-4E3B-B86D-8AED718DFE6CQ24299939-8EE4F8D8-6A3B-48E2-BA4F-656E807E1F8DQ26866451-DFCA8403-0D9A-46D0-8F61-B05FF63CE511Q27022109-BC7C2F1D-D6EF-4CE7-B656-9DADD667604BQ28388674-8F276CBA-AAEC-44A7-9C41-E5E91D715EBEQ28513036-121D7DF5-72A7-470E-AE82-4BA2E240179CQ30530939-C7CA8E58-D425-4F08-8125-7E813252B744Q30573767-F97F1898-D3E2-4DC5-95E5-726ECECCBBABQ30829363-4C667CEB-D62D-4573-8F6C-760552FD9272Q31041660-D6DA1D63-2EC7-423B-91B1-76524638DE9AQ33652645-F80FE53A-1DB9-4FF6-9FAD-1DBB32A707DCQ33733264-845EACCC-186E-4FA4-8D9F-8668D74B9561Q33771544-0E14B4D6-9FAA-4E15-9B10-3941209E63EFQ34553777-5F7E0785-BEA0-48ED-91E5-0F850974D1DDQ34604083-1ACCD1E8-E8F1-40E2-AD33-04EECADD8107Q35573431-CB2C6BBC-0C07-471D-A4DA-45682ABCE33FQ35927013-60CB18D6-D25C-4FD8-8CC9-5F5C4326900FQ36176035-D8031617-6D5D-4A3E-B73E-3059510179F4Q36227281-95A1AEBD-509C-453E-B8AE-9EF7D801D12BQ36499640-6AE86749-B561-4C1A-AF9C-0C7A7E880C17Q36516918-F4C02D16-A7E1-4734-941D-813BFA1E4A75Q36660994-544C15FF-F55C-4C86-8D60-BE75764BB47CQ36771898-CAF9EF41-286B-48E8-B1D4-E07E2D9DC279Q37030048-3233EFB3-AE0E-48EF-803C-ECEE901B0232Q37098892-DE1E2666-5F1C-4A9D-AE8C-4EB0C89C89A1Q37151410-0D4252D7-2776-4B90-80B3-A694A90ACE97Q37178950-2F6F3FE9-129E-441E-9C29-733BD1D823C1Q37602233-FBAFB26C-31CD-467E-99B4-C057608D7C9EQ37724701-5170E9A8-54A2-42FD-9A5E-559C5723A6F1Q37882576-81DCA92F-EECA-4A19-A419-F044A62073FEQ37910636-AA9ED235-8C40-4290-A124-DB7C6F854E67Q37997386-3FC25D8C-8734-4E2B-8610-128A62732090Q38038544-778D341F-FB99-41A7-A41C-7D7B37C1801FQ38188556-520F618B-703B-4566-8481-CCA3B5B74179Q38788917-FE79D836-53C0-43F4-B3B8-1F610FB46B84Q39067542-D9515EC1-1F50-4A6D-B620-15F585601E21Q39647087-950A8E7A-F8A9-4A94-8C73-3A8DAC7C5162Q40204484-2D7009B8-6432-4244-AA65-B106D82A76F4Q41828029-7B72B0D2-C965-4C75-BA19-EFE320F74F1B
P2860
Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@ast
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@en
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@nl
type
label
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@ast
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@en
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@nl
prefLabel
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@ast
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@en
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@nl
P50
P356
P1433
P1476
Clinical and subclinical dopam ...... sonism: an 18F-dopa PET study.
@en
P2093
Naheed L Khan
Paola Piccini
P304
P356
10.1002/ANA.10417
P577
2002-12-01T00:00:00Z